EasyDNNNewsCalendar

Archive

EasyDNNNews

Friday, May 8, 2020

Immunotherapy improves outcome in high-risk, HER2-negative breast cancer

Reuters (5/8) reports that adding the immune-checkpoint inhibitor durvalumab and the PARP inhibitor olaparib to standard neoadjuvant chemotherapy may improve outcome in women with high-risk, HER2-negative breast cancer, according to results of the I-SPY 2 trial, presented during the 2020 AACR Virual Annual Meeting.

Print
Author: Nicole Hardy
0 Comments

Categories: 2020, May, News, Screening and MammographyNumber of views: 127

Tags: